UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Crossfield SSR
(2022)
Interplay between demographic, clinical and polygenic risk factors for severe COVID-19.
in International journal of epidemiology
Cruz-Piedrahita C
(2022)
Holistic approach to assess the association between the synergistic effect of physical activity, exposure to greenspace, and fruits and vegetable intake on health and wellbeing: Cross-sectional analysis of UK Biobank.
in Frontiers in public health
Cui F
(2023)
Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis.
in The European respiratory journal
Cui T
(2022)
Gene-gene interaction detection with deep learning
in Communications Biology
Cullen B
(2019)
Understanding cognitive impairment in mood disorders: mediation analyses in the UK Biobank cohort.
in The British journal of psychiatry : the journal of mental science
Cullen B
(2018)
Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
in Scientific Reports
Cumplido-Mayoral I
(2022)
Biological Brain Age Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration
in Alzheimer's & Dementia
Cunningham JW
(2023)
Machine Learning to Understand Genetic and Clinical Factors Associated With the Pulse Waveform Dicrotic Notch.
in Circulation. Genomic and precision medicine
Cupido A
(2022)
Low-Density Lipoprotein Cholesterol Attributable Cardiovascular Disease Risk Is Sex Specific
in Journal of the American Heart Association
Cupido AJ
(2022)
Joint Genetic Inhibition of PCSK9 and CETP and the Association With Coronary Artery Disease: A Factorial Mendelian Randomization Study.
in JAMA cardiology
Currant H
(2021)
Genetic variation affects morphological retinal phenotypes extracted from UK Biobank optical coherence tomography images.
in PLoS genetics
Curta A
(2021)
Subclinical Changes in Cardiac Functional Parameters as Determined by Cardiovascular Magnetic Resonance (CMR) Imaging in Sleep Apnea and Snoring: Findings from UK Biobank.
in Medicina (Kaunas, Lithuania)
Curtis D
(2022)
Clinical features of UK Biobank subjects carrying loss of function variants in genes implicated in schizophrenia pathogenesis
in European Psychiatry
Curtis D
(2022)
Analysis of rare coding variants in 200,000 exome-sequenced subjects reveals novel genetic risk factors for type 2 diabetes.
in Diabetes/metabolism research and reviews
Curtis D
(2022)
Weighted burden analysis in 200,000 exome-sequenced subjects characterises rare variant effects on BMI.
in International journal of obesity (2005)
Curtis D
(2020)
Multiple Linear Regression Allows Weighted Burden Analysis of Rare Coding Variants in an Ethnically Heterogeneous Population.
in Human heredity
Curtis D
(2022)
Analysis of 200 000 exome-sequenced UK Biobank subjects illustrates the contribution of rare genetic variants to hyperlipidaemia.
in Journal of medical genetics
Curtis D
(2020)
Analysis of exome-sequenced UK Biobank subjects implicates genes affecting risk of hyperlipidaemia.
in Molecular genetics and metabolism
Curtis D
(2021)
Analysis of 200,000 Exome-Sequenced UK Biobank Subjects Implicates Genes Involved in Increased and Decreased Risk of Hypertension.
in Pulse (Basel, Switzerland)
Curtis D
(2021)
Haploinsufficiency of the HIRA gene may not always produce severe neurodevelopmental consequences.
in Psychiatric genetics
Curtis D
(2021)
Analysis of 50,000 exome-sequenced UK Biobank subjects fails to identify genes influencing probability of developing a mood disorder resulting in psychiatric referral.
in Journal of affective disorders
Curtis D
(2022)
Clinical features of UK Biobank subjects carrying protein-truncating variants in genes implicated in schizophrenia pathogenesis.
in Psychiatric genetics
Curtis D
(2020)
Variants in ACE2 and TMPRSS2 Genes Are Not Major Determinants of COVID-19 Severity in UK Biobank Subjects.
in Human heredity
Curtis EM
(2022)
Telomere Length and Risk of Incident Fracture and Arthroplasty: Findings From UK Biobank.
in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Cushing KC
(2022)
Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer.
in Inflammatory bowel diseases
Córdova-Palomera A
(2019)
Association between the 4p16 genomic locus and different types of congenital heart disease: results from adult survivors in the UK Biobank.
in Scientific reports
Córdova-Palomera A
(2020)
Cardiac Imaging of Aortic Valve Area From 34 287 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic Comorbidity With Multiple Disease Phenotypes.
in Circulation. Genomic and precision medicine
D'Antona S
(2022)
Consequences of exposure to pollutants on respiratory health: From genetic correlations to causal relationships.
in PloS one
D'Silva S
(2022)
Concurrent outcomes from multiple approaches of epistasis analysis for human body mass index associated loci provide insights into obesity biology.
in Scientific reports
D'Urso S
(2022)
Mendelian randomization analysis of factors related to ovulation and reproductive function and endometrial cancer risk.
in BMC medicine
Dabbah MA
(2021)
Machine learning approach to dynamic risk modeling of mortality in COVID-19: a UK Biobank study.
in Scientific reports
Dadi K
(2021)
Population modeling with machine learning can enhance measures of mental health.
in GigaScience
Daghlas I
(2019)
Sleep Duration and Myocardial Infarction.
in Journal of the American College of Cardiology
Daghlas I
(2021)
Selection into shift work is influenced by educational attainment and body mass index: a Mendelian randomization study in the UK Biobank.
in International journal of epidemiology
Dagliati A
(2021)
Sex and APOE genotype differences related to statin use in the aging population.
in Alzheimer's & dementia (New York, N. Y.)
Dahlqvist A
(2022)
POS0318 CHRONIC WIDESPREAD PAIN AND MORTALITY - A 25 YEAR FOLLOW UP
in Annals of the Rheumatic Diseases
Dahlqwist E
(2020)
Using instrumental variables to estimate the attributable fraction.
in Statistical methods in medical research
Dahlén AD
(2022)
The influence of personality on the risk of myocardial infarction in UK Biobank cohort.
in Scientific reports
Dai L
(2023)
Defining reference values for body composition indices by magnetic resonance imaging in UK Biobank.
in Journal of cachexia, sarcopenia and muscle
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |